|
|
|
Volumn 5, Issue 6, 2003, Pages 673-679
|
|
Technology evaluation: Pegaptanib, Eyetech/Pfizer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
APTAMER;
PEGAPTANIB;
POLYGLACTIN;
VASCULOTROPIN;
VASCULOTROPIN ANTIBODY;
ARTICLE;
BIOTECHNOLOGY;
CANCER;
CLINICAL TRIAL;
DIABETES MELLITUS;
DIABETIC RETINOPATHY;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG DELIVERY SYSTEM;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG METABOLISM;
DRUG SAFETY;
DRUG STABILITY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
EYE DISEASE;
HUMAN;
NONHUMAN;
RETINA MACULA AGE RELATED DEGENERATION;
RETINA MACULA EDEMA;
SIDE EFFECT;
STRUCTURE ACTIVITY RELATION;
TREATMENT INDICATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DIABETIC RETINOPATHY;
HUMANS;
MACULAR DEGENERATION;
NEOVASCULARIZATION, PATHOLOGIC;
RETINAL NEOVASCULARIZATION;
STRUCTURE-ACTIVITY RELATIONSHIP;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 0345827805
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (44)
|
|
References (0)
|
